Understanding the TRANSFORM-HF Trial: BAPA Members for Summer Convention Only
August 20, 2023
Target Audience
All pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to:
Identify the risk factors and symptoms of Heart Failure
Understand the differences between Furosemide and Torsemide as per the TRANSFORM-HF trial
Recognize the treatments and understand current treatment guidelines for Heart Failure
State the difference between treatment options for heart Failure particularly between Torsemide and
Furosemide
Hilton Philadelphia at Penn's Landing
201 S Christopher Columbus Blvd.
Philadelphia, PA
United States
Rafi Reyasat- Regional Medical Director- Urologic Oncology- Merck Rafi Reyasat is a Regional Medical Director for Urologic Oncology at Merck. Rafi completed his PharmD at St. John’s University and went on to complete his Post-Doctoral fellowship in GU Oncology Medical Affairs with Rutgers University and Pfizer. Rafi has worked in the GU oncology space for 5 years in roles of increasing responsibility at Pfizer and Merck
ACPE UAN # 0042-9999-23-073-L01-P
Available Credit
- 2.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.